Cancer Basic Biology Program The Cancer Basic Biology Program (CBB) aims to understand the fundamental genomic and cellular mechanisms that regulate the normal and transformed phenotype; to develop new molecular approaches and tools to advance cancer diagnosis and therapy; and to develop with other Consortium programs the intellectual and technical infrastructure to advance translational cancer research. There are three major scientific themes: 1. The biology of the nucleus in normal and tumor cells, with a focus on mechanisms regulating altered gene expression and the loss of genome stability in cancer; 2. Regulation of normal and cancer cell phenotypes including the regulation of the cell cycle and motility, and the use of genetic, metabolic and high-throughput screening strategies to improve cancer diagnosis and therapy; and 3. Protein design and genome engineering as enabling technologies to advance basic and translational cancer biology. The CCSG supports this research program by providing key shared resources, particularly Genomics, Proteomics, Cellular Imaging and Comparative Medicine; administrative support for meetings, clubs and interest groups; and pilot funding and new investigator funds. The Cancer Basic Biology Program currently has 73 members from 18 departments and 2 Institutions. 42 members have primary appointments at FHCRC and 31 at UW. 68 Members (93%) have peer-reviewed funding or are newly recruited and supported by their institution. The Cancer Basic Biology Program currently has $32.6M in peer-reviewed funding (direct) $7.1 of which (21%) is from NCI. Due to the tradition of basic research in small independent laboratories, most support is in the form of R01s. The Cancer Basic Biology Program published a total of 1116 papers in the previous grant period: 12% were intra-programmatic, 17% were inter-programmatic, and 11% were inter-institutional.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA015704-44
Application #
9617722
Study Section
Subcommittee I - Career Development (NCI)
Project Start
Project End
Budget Start
2019-01-01
Budget End
2019-12-31
Support Year
44
Fiscal Year
2019
Total Cost
Indirect Cost
Name
Fred Hutchinson Cancer Research Center
Department
Type
DUNS #
078200995
City
Seattle
State
WA
Country
United States
Zip Code
98109
Holly, Mayumi K; Smith, Jason G (2018) Adenovirus infection of human enteroids reveals interferon sensitivity and preferential infection of goblet cells. J Virol :
Cheng, Heather H (2018) The resounding effect of DNA repair deficiency in prostate cancer. Urol Oncol 36:385-388
Poudel, Kumud R; Roh-Johnson, Minna; Su, Allen et al. (2018) Competition between TIAM1 and Membranes Balances Endophilin A3 Activity in Cancer Metastasis. Dev Cell 45:738-752.e6
Eaton, Keith D; Romine, Perrin E; Goodman, Gary E et al. (2018) Inflammatory Gene Polymorphisms in Lung Cancer Susceptibility. J Thorac Oncol 13:649-659
Bar, Merav; Flowers, Mary E D; Storer, Barry E et al. (2018) Reversal of Low Donor Chimerism after Hematopoietic Cell Transplantation Using Pentostatin and Donor Lymphocyte Infusion: A Prospective Phase II Multicenter Trial. Biol Blood Marrow Transplant 24:308-313
Gauthier, Jordan; Turtle, Cameron J (2018) Insights into cytokine release syndrome and neurotoxicity after CD19-specific CAR-T cell therapy. Curr Res Transl Med 66:50-52
Graves, Scott S; Parker, Maura H; Stone, Diane et al. (2018) Anti-Inducible Costimulator Monoclonal Antibody Treatment of Canine Chronic Graft-versus-Host Disease. Biol Blood Marrow Transplant 24:50-54
Méndez, Eduardo; Rodriguez, Cristina P; Kao, Michael C et al. (2018) A Phase I Clinical Trial of AZD1775 in Combination with Neoadjuvant Weekly Docetaxel and Cisplatin before Definitive Therapy in Head and Neck Squamous Cell Carcinoma. Clin Cancer Res 24:2740-2748
Amundsen, Susan K; Smith, Gerald R (2018) The RecB helicase-nuclease tether mediates Chi hotspot control of RecBCD enzyme. Nucleic Acids Res :
Montgomery, Elizabeth T; Noguchi, Lisa M; Dai, James Y et al. (2018) Acceptability of and Adherence to an Antiretroviral-Based Vaginal Microbicide among Pregnant Women in the United States. AIDS Behav 22:402-411

Showing the most recent 10 out of 1267 publications